Skip to main
SKIN
SKIN logo

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health's fourth-quarter revenue of $96.8 million exceeded both internal estimates and broader market expectations, indicating robust demand for its products, particularly consumables. The average selling price (ASP) for total systems increased approximately 20% quarter-over-quarter to $28.8K, significantly surpassing earlier projections, driven by a higher percentage of direct sales as opposed to distributor orders. Although EBITDA guidance remains back-end weighted, the overall revenue performance and strong ASP growth underscore a positive trajectory for the company's financial health.

Bears say

Beauty Health Co. is facing significant challenges, with core delivery system placements declining over 30% year-over-year and quarter-over-quarter, falling short of previous expectations. This deceleration in new system placements raises concerns about future consumables sales, which are critical for reaching profitability goals in 2024. Additionally, management's first-quarter guidance for sales and adjusted EBITDA indicates expectations that are substantially below prior estimates, contributing to a negative outlook on the company's financial health.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.